Undisclosed Next-Gen Therapies
Geographic Atrophy (GA) / Age-related Macular Degeneration (AMD)
UnspecifiedDevelopment stated but no recent clinical activity; likely dormant.
Key Facts
Indication
Geographic Atrophy (GA) / Age-related Macular Degeneration (AMD)
Phase
Unspecified
Status
Development stated but no recent clinical activity; likely dormant.
Company
About Oxurion
Oxurion, founded in 1997 and listed on Euronext Brussels, is a biotech company in a significant strategic transition. Its core mission remains the development of novel therapies for serious retinal diseases to prevent blindness. However, its current and actively executed strategy is to build a diversified service group by acquiring majority stakes in pharmaceutical subcontractors, starting with a 72% stake in Axiodis CRO, aiming for more stable revenue streams alongside its R&D efforts.
View full company profile